Rockefeller Capital Management L.P. Neurocrine Biosciences Inc Transaction History

Rockefeller Capital Management L.P.

$36.3 Billion
Q3 2024

A detailed history of Rockefeller Capital Management L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 19,321 shares of NBIX stock, worth $2.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,321

Previous 19,277 0.23%

Holding current value

$2.42 Million

Previous $2.65 Million 16.17%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $5,041 - $6,738	44 Added 0.23%	19,321 $2.22 Million
Q2 2024 Aug 12, 2024	BUY	$130.86 - $143.19 $2.52 Million - $2.76 Million	19,277 New	19,277 $2.65 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $19,607 - $22,966	219 Added 3.26%	6,945 $654,000
Q1 2023 May 17, 2023	SELL	$94.11 - $123.02 $27,762 - $36,290	-295 Reduced 4.2%	6,726 $680,000
Q4 2022 Mar 06, 2023	SELL	$106.72 - $127.06 $6,296 - $7,496	-59 Reduced 0.83%	7,021 $838,000
Q3 2022 Nov 02, 2022	SELL	$92.03 - $107.81 $13,712 - $16,063	-149 Reduced 2.06%	7,080 $751,000
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $402,672 - $531,671	-5,313 Reduced 42.36%	7,229 $703,000
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $14,417 - $18,867	-199 Reduced 1.56%	12,542 $1.18 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $691,362 - $921,989	-8,680 Reduced 40.52%	12,741 $1.08 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $51.6 Million - $59.3 Million	-599,300 Reduced 96.55%	21,421 $2.05 Million
Q2 2021 Aug 10, 2021	SELL	$89.43 - $102.27 $194,599 - $222,539	-2,176 Reduced 0.35%	620,721 $60.4 Million
Q1 2021 May 11, 2021	BUY	$87.57 - $119.4 $1.4 Million - $1.91 Million	16,005 Added 2.64%	622,897 $60.6 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $23.8 Million - $29.7 Million	273,732 Added 82.16%	606,892 $58.2 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $24,905 - $35,003	259 Added 0.08%	333,160 $32 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $1.75 Million - $2.69 Million	20,607 Added 6.6%	332,901 $40.6 Million
Q1 2020 May 12, 2020	SELL	$75.11 - $113.76 $763,192 - $1.16 Million	-10,161 Reduced 3.15%	312,294 $27 Million
Q4 2019 Feb 07, 2020	SELL	$86.8 - $118.57 $2.51 Million - $3.43 Million	-28,925 Reduced 8.23%	322,455 $34.7 Million
Q3 2019 Nov 12, 2019	SELL	$83.82 - $101.5 $1.12 Million - $1.36 Million	-13,391 Reduced 3.67%	351,380 $31.7 Million
Q2 2019 Aug 09, 2019	BUY	$72.24 - $91.27 $10.1 Million - $12.8 Million	139,794 Added 62.14%	364,771 $30.8 Million
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $15.3 Million - $20.3 Million	221,302 Added 6021.82%	224,977 $19.8 Million
Q1 2018 May 09, 2018	BUY	$75.88 - $92.43 $278,859 - $339,680	3,675 New	3,675 $305,000

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.

Account

Rockefeller Capital Management L.P. Neurocrine Biosciences Inc Transaction History